Wednesday, October 12, 2016 4:00pm - 5:00pm
Watson CIT - SWIG Boardroom (CIT241)
Dr. Marco Gerlinger
Translational Oncogenomics Team Leader
Institute of Cancer Research, Centre for Evolution and Cancer
Tracking and Predicting Cancer Evolution
Intratumour heterogeneity and cancer evolution are critical for cancer progression and resistance development. Complex spatial clonal structures within solid tumour lesions and heterogeneity between metastatic sites have been demonstrated but detailed insights into the mechanisms shaping these heterogeneity landscapes and their relevance for cancer therapy are lacking. I will discuss our work that aims to dissect cancer evolution in kidney and gastro-esophageal cancers and which is providing increasingly detailed insights into phenotypic heterogeneity, the selection pressures which shape cancer evolution and the clinical implications. The impact of cancer evolution on rational drug therapy designs and on cancer predictability will also be discussed.